Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2009 1
2010 1
2011 1
2013 3
2014 1
2015 1
2016 2
2018 2
2020 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations.
Falcone I, Conciatori F, Bazzichetto C, Bria E, Carbognin L, Malaguti P, Ferretti G, Cognetti F, Milella M, Ciuffreda L. Falcone I, et al. Among authors: malaguti p. Int J Mol Sci. 2020 Nov 10;21(22):8419. doi: 10.3390/ijms21228419. Int J Mol Sci. 2020. PMID: 33182542 Free PMC article. Review.
[Pharmacogenomics and chemotherapy].
Paris I, Cappellini GC, Malaguti P, Bassanelli M, Marchetti P. Paris I, et al. Among authors: malaguti p. Recenti Prog Med. 2010 Jul-Aug;101(7-8):277-82. Recenti Prog Med. 2010. PMID: 20842953 Review. Italian.
Palbociclib: efficacious but predictive biomarkers still needed.
Cognetti F, Malaguti P, Alesini D. Cognetti F, et al. Among authors: malaguti p. Lancet Oncol. 2016 Apr;17(4):402-403. doi: 10.1016/S1470-2045(16)00144-3. Epub 2016 Mar 3. Lancet Oncol. 2016. PMID: 26947329 No abstract available.
The immersive experience of virtual reality during chemotherapy in patients with early breast and ovarian cancers: The patient's dream study.
Fabi A, Fotia L, Giuseppini F, Gaeta A, Falcicchio C, Giuliani G, Savarese A, Taraborelli E, Rossi V, Malaguti P, Giannarelli D, Pugliese P, Cognetti F. Fabi A, et al. Among authors: malaguti p. Front Oncol. 2022 Sep 30;12:960387. doi: 10.3389/fonc.2022.960387. eCollection 2022. Front Oncol. 2022. PMID: 36249001 Free PMC article.
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study.
Turinetto M, Ricotti A, Marchetti C, Pisano C, Zamagni C, Cassani C, Malaguti P, Baldoni A, Scollo P, Scandurra G, Parisi A, Artioli G, Palaia I, Vertechy L, Bergamini A, Picardo E, Tuninetti V, Scotto G, Scambia G, Pignata S, Valabrega G. Turinetto M, et al. Among authors: malaguti p. Cancers (Basel). 2023 Dec 20;16(1):41. doi: 10.3390/cancers16010041. Cancers (Basel). 2023. PMID: 38201470 Free PMC article.
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer.
Fabi A, Alesini D, Valle E, Moscetti L, Caputo R, Caruso M, Carbognin L, Ciccarese M, La Verde N, Arpino G, Cannita K, Paris I, Santini D, Montemurro F, Russillo M, Ferretti G, Filippelli G, Rossello R, Fabbri A, Zambelli A, Leonardi V, D'Ottavio AM, Nisticò C, Stani S, Giampaglia M, Scandurra G, Catania G, Malaguti P, Giannarelli D, Cognetti F. Fabi A, et al. Among authors: malaguti p. Breast. 2018 Oct;41:137-143. doi: 10.1016/j.breast.2018.07.004. Epub 2018 Jul 12. Breast. 2018. PMID: 30092500
19 results